Aimmune Therapeutics (AIMT) Reports Licensing of Exclusive Worldwide Rights to Xencor (XNCR) XmAb7195 for Development of Next-Generation Food Allergy Treatments
Go back to Aimmune Therapeutics (AIMT) Reports Licensing of Exclusive Worldwide Rights to Xencor (XNCR) XmAb7195 for Development of Next-Generation Food Allergy Treatments| AIMSI Technologies (NASDAQ: AIMT) | Delayed: 34.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.49 | 52 Week High | $27.31 | |||
| Open | $7.76 | 52 Week Low | $9.77 | |||
| Day High | $34.49 | P/E | N/A | |||
| Day Low | $34.49 | EPS | $0.00 | |||
| Volume | 42,896 | |||||
| XENCOR (NASDAQ: XNCR) | Delayed: 14.39 +0.38 (2.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.01 | 52 Week High | $26.50 | |||
| Open | $13.90 | 52 Week Low | $9.89 | |||
| Day High | $14.50 | P/E | N/A | |||
| Day Low | $13.90 | EPS | $-0.51 | |||
| Volume | 435,642 | |||||
